Intradigm’s lead product candidate ICS-283 is a nanoparticle-based siRNA targeting the VEGF (Vascular Endothelial Growth Factor) pathway. The product uses an RGD peptide as the ligand to target av-expressing endothelial cells. ICS-283 is currently in the preclinical stage. Data from several in vivo models including xenograft models of different cancers (colorectal, renal, head and neck, and breast) have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as a validated target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm systemic delivery of RNAi in man.
|11/21/06||Series A||16M||Alta Partners, Emerging Technology Partners, Frazier Healthcare Ventures, Genentech, MediBic Alliance/Daiichi, Novartis Ventures||Unknown|
|01/01/09||Series B||21.4M||Lilly Ventures, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, Novartis Venture Fund, Astellas Venture Management||Unknown|